ID: ALA2205662

Max Phase: Preclinical

Molecular Formula: C21H21N13O4

Molecular Weight: 519.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(N(CCn2nnc3c(C(N)=O)ncn3c2=O)CCn2nnc3c(C(N)=O)ncn3c2=O)cc1

Standard InChI:  InChI=1S/C21H21N13O4/c1-12-2-4-13(5-3-12)30(6-8-33-20(37)31-10-24-14(16(22)35)18(31)26-28-33)7-9-34-21(38)32-11-25-15(17(23)36)19(32)27-29-34/h2-5,10-11H,6-9H2,1H3,(H2,22,35)(H2,23,36)

Standard InChI Key:  SRFTZNAYQBILPX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 519.49

Molecular Weight (Monoisotopic): 519.1839

AlogP: -2.40

#Rotatable Bonds: 9

Polar Surface Area: 219.58

Molecular Species: NEUTRAL

HBA: 15

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 17

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.16

CX Basic pKa: 2.98

CX LogP: 1.69

CX LogD: 1.69

Aromatic Rings: 5

Heavy Atoms: 38

QED Weighted: 0.21

Np Likeness Score: -1.17

References

1. Garelnabi EA, Pletsas D, Li L, Kiakos K, Karodia N, Hartley JA, Phillips RM, Wheelhouse RT..  (2012)  Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.,  3  (12): [PMID:24900418] [10.1021/ml300132t]

2. Pletsas D, Garelnabi EA, Li L, Phillips RM, Wheelhouse RT..  (2013)  Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.,  56  (17): [PMID:23895620] [10.1021/jm401121k]

3. Fernandes GFDS, Fernandes BC, Valente V, Dos Santos JL..  (2019)  Recent advances in the discovery of small molecules targeting glioblastoma.,  164  [PMID:30583248] [10.1016/j.ejmech.2018.12.033]

Source

Source(1):

• Scientific Literature